Eurofins Scientific Stock: Over 2% Rebound After a Week of Decline
Eurofins Scientific stock is showing signs of recovery this Friday, February 13, with a 2.09% increase to 65.36 euros after several consecutive sessions of decline. This rebound occurs in a technically tense context, with the stock having lost nearly 4.5% over the past seven days. However, its annual performance remains solidly positive, at nearly 30%.
Eurofins Scientific's share price is currently at 65.36 euros, just above its 50-day moving average of 65.12 euros, a level that the stock briefly dipped below in recent sessions. If this upward crossing is confirmed at the close, it could represent a short-term stabilization point. The RSI indicator is at 24, well below the usual oversold threshold of 30, indicating a recent bearish excess and signaling that selling pressure has been particularly intense in recent sessions. The most relevant technical support is at 62.00 euros, a floor that was not tested during the recent correction, as the stock found a low near its 200-day moving average of 62.27 euros.
Overall Dynamics
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Despite the weekly decline, the overall momentum of the bioanalysis specialist remains positive. Over three months, the stock has gained 10.07%, while the annual performance reaches 29.48%. This trajectory reflects the progressive revaluation of the group, whose course has moved significantly away from its 200-day moving average, established at 62.27 euros. The monthly volatility, measured at 9%, remains contained for a stock in this segment, suggesting that recent movements are within usual ranges. The extremely low beta, at 0.02, further confirms the stock's low correlation with general market fluctuations. Today's rebound brings the price back to the lower part of the Bollinger bands, with the lower boundary at 64.31 euros, which served as a support zone in the previous session. The major resistance to watch is positioned at 73.12 euros, nearly 12% away from the current price.
SectorSanté · Vaccins et laboratoires de recherche›Services médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Contexte
Period
Period: 1T2026
Key reported figures
Revenue: 1789M€
Guidance from the release
Eurofins a rencontré des vents contraires importants et temporaires.
Malgré une croissance organique modérée, la rentabilité et les marges progressent.
Risks mentioned
Baisse de la demande en raison de conditions climatiques défavorables en Amérique du Nord.
Rationalisation des contrats dans les diagnostics cliniques en Espagne et en Italie.
Opportunities identified
Lancement de nouveaux contrats renforçant notre portefeuille BioPharma.
Initiatives de digitalisation et amélioration du réseau de laboratoires.
Les informations présentées dans cet article sont fournies à titre purement indicatif et ne constituent en aucun cas une recommandation d'investissement, une incitation à acheter ou vendre un actif financier, ni un conseil en placement. Le lecteur est invité à réaliser ses propres recherches avant toute décision.
Les investissements en bourse comportent des risques, notamment de perte en capital. La performance passée d'un actif ou d'un marché ne présage en rien de ses performances futures. Toute décision d'investissement doit être prise en tenant compte de votre situation financière personnelle, de vos objectifs et de votre tolérance au risque.